<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03246919</url>
  </required_header>
  <id_info>
    <org_study_id>209632</org_study_id>
    <nct_id>NCT03246919</nct_id>
  </id_info>
  <brief_title>Ideal Time of Oxytocin Infusion During Cesarean Section</brief_title>
  <acronym>I-TOPICS</acronym>
  <official_title>Ideal Time of Oxytocin Infusion During Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate if the timing of oxytocin administration in cesarean deliveries will
      affect the amount of maternal blood loss. Half of participants will receive oxytocin after
      delivery of the fetal anterior shoulder and the other half will receive oxytocin after
      delivery of the placenta. We hypothesize that administering oxytocin after delivery of the
      shoulder, will result in less overall maternal blood loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxytocin is a routinely administered medication for both vaginal and cesarean deliveries in
      the third stage of labor, as part of standard of care in the United States. This medication
      helps to reduce overall blood loss, by functioning as a uterotonic. Currently evidence is
      lacking to direct timing of oxytocin administration in cesarean deliveries.

      This study will evaluate both estimated and quantitative blood loss for both groups of
      patients. It will also compare the change from pre-operative to post-operative hemoglobin
      levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind: Obstetricians, Anesthesiologists and patients will be blinded. Only nurses will be aware of timing of oxytocin administration</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss</measure>
    <time_frame>At the completion of the surgery when patient is transferred to recovery from the operating room</time_frame>
    <description>Both the estimated blood loss and quantitative blood loss will be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postpartum hemorrhage</measure>
    <time_frame>At the completion of the surgery when patient is transferred to recovery from the operating room</time_frame>
    <description>The number of women who lose 1,000 milliliters or more blood from cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusion</measure>
    <time_frame>In the immediate 24 hours post surgery</time_frame>
    <description>The number of women who require a blood transfusion due to surgical blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre-operative to post-operative hemoglobin levels</measure>
    <time_frame>Baseline and Post operative day number 1</time_frame>
    <description>Hemoglobin levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <condition>Postpartum Hemorrhage</condition>
  <condition>Bleed Pregnancy</condition>
  <condition>Pregnancy Related</condition>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>Control (Group A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention (Group B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta</description>
    <arm_group_label>Intervention (Group B)</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered after delivery of the placenta</description>
    <arm_group_label>Control (Group A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing cesarean section at Loyola Hospital

          -  Women who read and speak the English and/or Spanish language

          -  Women age 18 or older

        Exclusion Criteria:

          -  Women who deliver vaginally

          -  Gestation under 37 weeks and 0 days

          -  Women with coagulopathies

          -  Multiple gestation pregnancies

          -  Antepartum hemorrhage for example abruption

          -  Placental abnormalities for example previa, accreta
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thaddeus Waters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Whitney Dunn, MD</last_name>
    <phone>708-216-4033</phone>
    <email>whitney.dunn@lumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Dunn, MD</last_name>
      <phone>708-216-4033</phone>
      <email>whitney.dunn@lumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jackson KW Jr, Allbert JR, Schemmer GK, Elliot M, Humphrey A, Taylor J. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol. 2001 Oct;185(4):873-7.</citation>
    <PMID>11641669</PMID>
  </reference>
  <reference>
    <citation>Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD006173. doi: 10.1002/14651858.CD006173.pub2. Review.</citation>
    <PMID>20687079</PMID>
  </reference>
  <reference>
    <citation>Fidan U, Keskin U, Ulubay M, Efendi Karaca R, Burçin Fıratlıgil F, Göksen Kocagöz G, Ergün A. The effect of the use of oxytocin on blood loss during different postpartum periods. J Perinat Med. 2015 Jul;43(4):461-5. doi: 10.1515/jpm-2014-0111.</citation>
    <PMID>24897394</PMID>
  </reference>
  <reference>
    <citation>Oguz Orhan E, Dilbaz B, Aksakal SE, Altınbas S, Erkaya S. Prospective randomized trial of oxytocin administration for active management of the third stage of labor. Int J Gynaecol Obstet. 2014 Nov;127(2):175-9. doi: 10.1016/j.ijgo.2014.05.022. Epub 2014 Jul 17.</citation>
    <PMID>25108586</PMID>
  </reference>
  <reference>
    <citation>Dahlke JD, Mendez-Figueroa H, Rouse DJ, Berghella V, Baxter JK, Chauhan SP. Evidence-based surgery for cesarean delivery: an updated systematic review. Am J Obstet Gynecol. 2013 Oct;209(4):294-306. doi: 10.1016/j.ajog.2013.02.043. Epub 2013 Mar 1. Review.</citation>
    <PMID>23467047</PMID>
  </reference>
  <reference>
    <citation>Khan FA, Khan M, Ali A, Chohan U. Estimation of blood loss during Caesarean section: an audit. J Pak Med Assoc. 2006 Dec;56(12):572-5.</citation>
    <PMID>17312645</PMID>
  </reference>
  <reference>
    <citation>Anderson JM, Etches D. Prevention and management of postpartum hemorrhage. Am Fam Physician. 2007 Mar 15;75(6):875-82.</citation>
    <PMID>17390600</PMID>
  </reference>
  <reference>
    <citation>WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2012.</citation>
    <PMID>23586122</PMID>
  </reference>
  <reference>
    <citation>National Collaborating Centre for Women's and Children's Health. Caesarean section NICE Clinical Guideline. Royal College of Obstetricians and Gynaecologists</citation>
  </reference>
  <reference>
    <citation>Silverman, F. &amp; Bornstein, E. Pharmacologic management of the third stage of labor. UpToDate. 2015</citation>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Thaddeus Waters</investigator_full_name>
    <investigator_title>Maternal Fetal Medicine, Assistant Professor, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

